Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China
· Delayed Price · Currency is CNY 10.72
+0.17 (1.61%)
Apr 30, 2025, 3:00 PM CST
SHA:603567 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
| Operating Revenue | 3,063 | 3,084 | 4,199 | 4,120 | 3,390 | 2,944 | Upgrade
|
| Other Revenue | 54.11 | 54.11 | 14.68 | 6.5 | 14.22 | 348.09 | Upgrade
|
| Revenue | 3,117 | 3,138 | 4,214 | 4,127 | 3,404 | 3,292 | Upgrade
|
| Revenue Growth (YoY) | 5.96% | -25.53% | 2.12% | 21.24% | 3.40% | 18.37% | Upgrade
|
| Cost of Revenue | 1,672 | 1,846 | 3,539 | 2,829 | 1,515 | 1,385 | Upgrade
|
| Gross Profit | 1,446 | 1,292 | 675.25 | 1,298 | 1,888 | 1,906 | Upgrade
|
| Selling, General & Admin | 612.11 | 979.01 | 915.17 | 952.16 | 1,054 | 1,178 | Upgrade
|
| Research & Development | 48.8 | 80.22 | 70.95 | 55.23 | 81.34 | 86.5 | Upgrade
|
| Other Operating Expenses | 90.92 | 43.79 | -64.36 | -24.14 | 132.34 | 56.43 | Upgrade
|
| Operating Expenses | 760.27 | 1,107 | 891.96 | 1,028 | 1,303 | 1,340 | Upgrade
|
| Operating Income | 685.31 | 185.52 | -216.71 | 270.38 | 585.35 | 566.43 | Upgrade
|
| Interest Expense | -137.9 | -135.41 | -138.68 | -144.79 | -149.61 | -113.69 | Upgrade
|
| Interest & Investment Income | 365.04 | 471.68 | 38.06 | 251.32 | 31.87 | 13.44 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | -0 | -0 | -0 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -100.02 | -93.54 | 26.83 | -22.32 | -1.85 | -8.25 | Upgrade
|
| EBT Excluding Unusual Items | 812.42 | 428.24 | -290.5 | 354.6 | 465.76 | 457.93 | Upgrade
|
| Impairment of Goodwill | -2.4 | -2.4 | -1.28 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -4.04 | 0.6 | -1.75 | -0.15 | -16.98 | -3.73 | Upgrade
|
| Gain (Loss) on Sale of Assets | -174.2 | -1.68 | 39.33 | -1.11 | -0.21 | -0.06 | Upgrade
|
| Asset Writedown | -50.74 | -0.09 | - | -0.09 | - | -0.05 | Upgrade
|
| Legal Settlements | - | - | - | - | - | -8.7 | Upgrade
|
| Other Unusual Items | 96.95 | 53.67 | 552.68 | 101.49 | 88.68 | 91.94 | Upgrade
|
| Pretax Income | 678 | 478.35 | 298.48 | 454.75 | 537.25 | 537.33 | Upgrade
|
| Income Tax Expense | 31.63 | 10.76 | 107.55 | 121.99 | 99.75 | 131.48 | Upgrade
|
| Earnings From Continuing Operations | 646.37 | 467.59 | 190.93 | 332.76 | 437.5 | 405.84 | Upgrade
|
| Minority Interest in Earnings | 7.02 | 5.15 | -5.49 | -0.66 | -1.22 | 2.8 | Upgrade
|
| Net Income | 653.39 | 472.74 | 185.44 | 332.1 | 436.29 | 408.65 | Upgrade
|
| Net Income to Common | 653.39 | 472.74 | 185.44 | 332.1 | 436.29 | 408.65 | Upgrade
|
| Net Income Growth | 162.38% | 154.93% | -44.16% | -23.88% | 6.76% | -11.63% | Upgrade
|
| Shares Outstanding (Basic) | 940 | 939 | 941 | 865 | 849 | 849 | Upgrade
|
| Shares Outstanding (Diluted) | 941 | 940 | 941 | 865 | 849 | 849 | Upgrade
|
| Shares Change (YoY) | 0.19% | -0.14% | 8.87% | 1.82% | -0.01% | -0.83% | Upgrade
|
| EPS (Basic) | 0.70 | 0.50 | 0.20 | 0.38 | 0.51 | 0.48 | Upgrade
|
| EPS (Diluted) | 0.69 | 0.50 | 0.20 | 0.38 | 0.51 | 0.48 | Upgrade
|
| EPS Growth | 161.87% | 155.28% | -48.71% | -25.24% | 6.78% | -10.89% | Upgrade
|
| Free Cash Flow | -297.18 | -573.38 | -731.07 | -882.57 | -713.47 | 42.14 | Upgrade
|
| Free Cash Flow Per Share | -0.32 | -0.61 | -0.78 | -1.02 | -0.84 | 0.05 | Upgrade
|
| Dividend Per Share | 0.200 | 0.200 | 0.028 | 0.106 | - | 0.217 | Upgrade
|
| Dividend Growth | 614.29% | 614.29% | -73.58% | - | - | 32.32% | Upgrade
|
| Gross Margin | 46.37% | 41.18% | 16.02% | 31.45% | 55.48% | 57.92% | Upgrade
|
| Operating Margin | 21.98% | 5.91% | -5.14% | 6.55% | 17.20% | 17.21% | Upgrade
|
| Profit Margin | 20.96% | 15.06% | 4.40% | 8.05% | 12.82% | 12.41% | Upgrade
|
| Free Cash Flow Margin | -9.53% | -18.27% | -17.35% | -21.39% | -20.96% | 1.28% | Upgrade
|
| EBITDA | 869.81 | 358.22 | -59.75 | 405.93 | 741.23 | 704.85 | Upgrade
|
| EBITDA Margin | 27.90% | 11.42% | -1.42% | 9.84% | 21.78% | 21.41% | Upgrade
|
| D&A For EBITDA | 184.51 | 172.7 | 156.95 | 135.55 | 155.89 | 138.42 | Upgrade
|
| EBIT | 685.31 | 185.52 | -216.71 | 270.38 | 585.35 | 566.43 | Upgrade
|
| EBIT Margin | 21.98% | 5.91% | -5.14% | 6.55% | 17.20% | 17.21% | Upgrade
|
| Effective Tax Rate | 4.67% | 2.25% | 36.03% | 26.82% | 18.57% | 24.47% | Upgrade
|
| Revenue as Reported | 3,121 | 3,144 | 4,219 | 4,130 | 3,411 | 3,297 | Upgrade
|
| Advertising Expenses | - | 10.42 | 3.57 | 2.17 | 3.74 | 6.24 | Upgrade
|
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.